- Details
- Ashish Kamat hosts Janet Kukreja to discuss intravesical therapy for bladder cancer, providing a comprehensive overview of treatments such as BCG, gemcitabine, and mitomycin C. Dr. Kukreja emphasizes the importance of understanding patient risk categories and adhering to guidelines for treatment decisions. She addresses the ongoing BCG shortage in the U.S., discussing its impact on both treatment...
|
- Details
- In this discussion, Steven Boorjian and Kevin Wymer provide an insightful analysis on the cost-effectiveness of pembrolizumab for BCG-unresponsive carcinoma in situ of the bladder. Given its promising oncologic benefits but high cost and toxicity levels, they conduct a cost-effectiveness analysis comparing pembrolizumab, radical cystectomy, and salvage intravesical chemotherapy. Adopting an ICER (...
|
- Details
- Subtypes in non-muscle-invasive bladder cancer are not well-defined, whereas the molecular landscape of muscle-invasive bladder cancer is relatively well-established. During the optimizing personalized management of non-muscle-invasive bladder cancer session at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Eugene Pietzak, MD, discussed the molecular landscape...
|
- Details
- In this conversation with Ashish Kamat, Lars Dyrskjøt, an expert in the field of molecular markers and personalized medicine speaks about circulating tumor DNA and the potential as a tumor for guiding treatment decisions in bladder cancer. Cell-free DNA in the blood has a half-life of less than two hours, so it makes it possible to use it as a biomarker of the direct tumor burden and hence the det...
|
- Details
- Bernard Bochner joins Ashish Kamat in this discussion discussing the advancements throughout 2020 in muscle-invasive non-metastatic bladder cancer. It would be impossible to discuss the year without mentioning the impact of COVID-19. There are some diseases that can withstand treatment delay, but muscle-invasive bladder cancer is not one of those tumors. These challenges pushed the bladder cancer...
|
- Details
- The European Association of Urology (EAU) published its updated guideline recommendations for non-muscle invasive bladder cancer (NMIBC) in 2020. The updated EAU Guidelines stratify NMIBC into low, intermediate, and high risk for treatment options. In this conversations with Ashish Kamat, MD, MBBS, Marko Babjuk, MD, Ph.D., overviews the 2020 updated guidelines highlighting changes in the guideline...
|
- Details
- Alexander Wyatt from the University of British Columbia joins Ashish Kamat in a discussion on the genomic correlates of Bacillus Calmette-Guerin (BCG) responsive and relapsed non-muscle invasive bladder cancer. Dr. Wyatt shares recent study findings exploring links between common genomic driver alternations and BCG unresponsiveness and also data looking at genomic variables in the context of initi...
|
- Details
- In this conversation with Ashish Kamat, MD, Arjun Balar, MD, MBBS, discusses testing the concept of effectively treating bladder cancer without needing chemotherapy in the non-muscle-invasive disease space, specifically patients with high-risk carcinoma in situ, with or without papillary tumors that had become unresponsive to Bacillus Calmette-Guerin (BCG) based on the current Federal Drug Adminis...
|
- Details
- Ashish Kamat welcomes Karen Sachse, a patient advocate for the Bladder Cancer Advocacy Network (BCAN) who shares her perspective on non muscle-invasive bladder cancer, the various trials that are ongoing, and the future of various studies. As a bladder cancer survivor diagnosed in 2010 at age 54 with high grade non-muscle invasive bladder cancer, she is disease-free since 2014. Biographies: Karen...
|
- Details
- Co-chair of the Bacillus Calmette Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer session during the 2020 Virtual Bladder Cancer Advocacy Network Think Tank (BCANTT) meeting, Peter Black, MD joins Ashish Kamat, MD, MBBS providing a succinct overview of this session highlighting the clinical and the translational panel which addresses defining treatment failure after BCG treatment for...
|
